| Literature DB >> 34943672 |
Zorana Kovačević1, Nebojša Kladar2, Ivana Čabarkapa3, Miodrag Radinović1, Milan Maletić4, Mihajlo Erdeljan1, Biljana Božin2.
Abstract
Mastitis represents a heavy burden for the dairy sector worldwide with high economic and animal welfare impact. Antibiotic treatment is an important component of mastitis control programs. However, emergence and transfer of antimicrobial-resistant (AMR) bacteria is becoming a growing concern. Therefore, the development of novel agents is required for prevention and treatment of mastitis. Hence, our aim was to assess the antibacterial properties of two essential oils (EOs) obtained from oregano (Origanum vulgare L., Lamiaceae) and mountain savory (Satureja montana L., Lamiaceae) against mastitis-associated bacteria in Serbia. The chemical composition and antioxidant potential of these EOs were also evaluated. The present study was conducted on strains derived from aseptic milk samples collected from Holstein-Friesian cows with clinical or subclinical mastitis, during the morning milking. Clinical mastitis was assessed by clinical examination, while subclinical mastitis was confirmed using somatic cell count in the milk samples. The microdilution method was used to determine the antibacterial activity, while antioxidant potential of the EOs was evaluated in several in vitro assays. The values of minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were used to quantitatively measure the antibacterial activity of each EO. MIC/MBC ranged from 0.78/6.25 and 0.39/0.78 mg/mL for oregano and mountain savory, respectively. A total of 25 compounds were identified in the oregano EO, while 47 were identified in winter savory EO, among which aromatic oxygenated monoterpenes were the most abundant compounds. The tested EOs have shown promising antimicrobial activity and could be considered as one of the treatment approaches in mastitis-affected cows.Entities:
Keywords: antibacterial activity; antibiotics; antioxidant; essential oil; mastitis-causing bacteria; oregano; winter savory
Year: 2021 PMID: 34943672 PMCID: PMC8698621 DOI: 10.3390/antibiotics10121460
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Antibiotic susceptibility patterns for the mastitis-associated bacteria (S—sensitive, I—intermediate, R—resistant). AMX, amoxycillin; AMP, ampicillin; CRO, ceftriaxone; ENR, enrofloxacin; ERY, erythromycin; LIN, lincomycin; NEO, neomycin; PEN, penicillin; STR, streptomycin; TET, tetracycline; AMC, amoxicillin/clavulanic acid; NB, novobiocin; SXT, trimethoprim/sulfamethoxazole; CLO, cloxacillin. Streptococcus spp. β heamoliticus (Strep_bh), Streptococcus spp. (Strep), Staphylococcus spp. coagulase negative (Staph_cn), E. coli (E_c), Klebsiella oxytoca (K_o), Enterobacter sakazakii (E_s), Staphylococcus aureus (Staph_a), Streptococcus dysgalactiae (Strep_d), and Streptococcus uberis (Strep_u).
| Bacterial Strains Culture | AMX | AMP | CRO | ENR | ERY | GEN | LIN | NEO | PEN | STR | TET | AMC | NB | SXT | CLO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strep_bh | S | S | S | S | S | R | S | R | R | S | S | S | S | R | R |
| Strep | R | R | R | R | R | I | R | R | R | S | R | R | R | R | R |
| Strep | R | R | R | R | R | I | R | R | R | S | R | R | R | R | R |
| Staph_cn | S | S | I | S | S | S | S | S | R | S | S | S | S | S | R |
| Strep | R | R | R | R | I | S | R | R | R | S | R | R | R | R | R |
| Strep_bh | I | R | S | S | R | S | R | S | R | S | I | S | I | S | R |
| E_c | R | R | R | S | R | S | R | S | R | S | R | R | R | S | R |
| E_c | R | R | R | S | R | S | R | S | R | S | I | R | R | S | R |
| Strep_bh | R | R | S | S | R | S | R | S | R | S | R | S | R | R | R |
| K_o | R | R | S | S | R | S | R | S | R | S | R | R | R | S | R |
| E_c | R | R | R | S | R | S | R | S | R | S | I | R | R | S | R |
| Strep | R | R | I | S | R | S | I | R | R | S | R | S | R | R | R |
| E_c | R | R | R | S | R | S | R | S | R | S | R | R | R | S | R |
| E_s | R | R | R | S | R | S | R | S | R | S | S | R | R | S | R |
| Staph_a | I | R | S | S | S | S | S | S | R | S | S | S | S | S | R |
| E_c | I | R | S | S | R | S | R | S | R | S | I | S | R | S | R |
| Strep_u | S | S | I | S | I | S | R | R | R | S | S | S | R | R | R |
| E_c | I | R | S | S | R | S | R | S | R | S | S | S | R | S | R |
| Staph_a | I | R | S | S | S | S | S | S | R | S | S | S | S | S | R |
| Strep_d | S | R | R | S | I | I | R | R | R | S | R | S | I | R | R |
| Strep | S | S | S | S | S | S | R | R | R | R | R | S | R | R | R |
Chemical composition of Origanum vulgare (Ov) and Satureja montana (Sm) EOs (%).
| Peack No. | Compound | RI * |
|
|
|---|---|---|---|---|
| Monoterpene Hydrocarbons | 3.53 | 18.47 | ||
| 1 | α-Thujene | 930 | n.d. | 1.28 |
| 2 | α-Pinene | 937 | 0.26 | 0.81 |
| 3 | Camphene | 952 | 0.09 | 0.38 |
| 4 | β-Pinene | 978 | 0.53 | 0.83 |
| 5 | β-Myrcene | 991 | 0.27 | 1.06 |
| 7 | α-Phellandrene | 1005 | 0.04 | 0.23 |
| 8 | δ-3-Carene | 1011 | n.d. | 0.06 |
| 9 | α-Terpinene | 1017 | 0.36 | 2.01 |
| 11 | Limonene | 1030 | 0.45 | 0.52 |
| 13 | β-Ocimene | 1037 | n.d. | 0.06 |
| 14 | γ-Terpinene | 1060 | 1.53 | 11.09 |
| 16 | Terpinolene | 1088 | n.d. | 0.14 |
| Aromatic Monoterpene Hydrocarbons | 4.82 | 14.71 | ||
| 10 | p-Cymene | 1025 | 4.82 | 14.71 |
| Oxygenated Monoterpenes | 2.58 | 3.81 | ||
| 12 | 1,8-Cineole | 1032 | 0.51 | 0.32 |
| 15 | cis-Sabinene hydrate | 1070 | n.d. | 0.24 |
| 17 | Linalool | 1099 | 0.97 | 0.81 |
| 18 | Camphor | 1145 | 0.04 | 0.05 |
| 19 | endo-Borneol | 1167 | 0.41 | 1.04 |
| 20 | Terpinen-4-ol | 1177 | 0.52 | 0.75 |
| 21 | α-Terpineol | 1189 | 0.13 | 0.26 |
| 22 | Carvone | 1242 | n.d. | 0.15 |
| 27 | Geranyl acetate | 1382 | n.d. | 0.19 |
| Aromatic Oxygenated Monoterpenes | 84.56 | 55.34 | ||
| 23 | Thymol | 1291 | 4.21 | 0.33 |
| 24 | Carvacrol | 1299 | 80.35 | 55.01 |
| Sesquiterpene Hydrocarbons | 2.96 | 6.96 | ||
| 25 | α-Cubebene | 1351 | 0.03 | 0.05 |
| 26 | α-Copaene | 1376 | n.d. | 0.16 |
| 28 | (-)-β-Bourbonene | 1384 | n.d. | 0.15 |
| 29 | β-Cubenene | 1388 | n.d. | 0.03 |
| 30 | Longifolene | 1408 | n.d. | 0.51 |
| 31 | trans-β-Caryophyllene | 1419 | 2.02 | 2.26 |
| 32 | β-Copaene | 1432 | n.d. | 0.08 |
| 33 | γ-Elemene | 1433 | n.d. | 0.03 |
| 34 | Aromandendrene | 1440 | n.d. | 0.12 |
| 35 | cis-β-Famesene | 1443 | n.d. | 0.02 |
| 36 | Humulene | 1454 | 0.24 | 0.08 |
| 37 | trans-β-Famesene | 1456 | 0.21 | n.d. |
| 38 | allo-Aromandendrene | 1461 | n.d. | 0.18 |
| 39 | γ-Muurolene | 1477 | n.d. | 0.24 |
| 40 | Germacrene D | 1482 | 0.03 | 0.58 |
| 41 | β-Selinene | 1486 | n.d. | 0.21 |
| 42 | α-Muurolene | 1499 | n.d. | 0.09 |
| 43 | β-Bisabolene | 1509 | n.d. | 1.51 |
| 44 | γ-Cadinene | 1513 | n.d. | 0.2 |
| 45 | δ-Cadinene | 1524 | 0.43 | 0.46 |
| Oxygenated Sesquiterpenes | 0.93 | 0.35 | ||
| 46 | Caryophyllenyl alcohol | 1572 | 0.00 | 0.06 |
| 47 | Caryophyllene oxide | 1581 | 0.93 | 0.27 |
| 48 | α-Cadinol | 1653 | n.d. | 0.02 |
| Aliphatic Compunds | 0.04 | 0.02 | ||
| 6 | 3-Octanol | 994 | 0.04 | 0.02 |
| TOTAL OF IDENTIFIED COMPOUNDS | 99.42 | 99.66 | ||
* Retention indices relative to C9-C24 n-alkanes on the HP 5MS column; n.d.—not detected.
Antioxidant potential of the tested EOs of O. vulgare and S. montana and positive control substances (AA—ascorbic acid; PG—propyl gallate; BHT—tert-butylated hydroxytoluene). FRAP, ferric reduction antioxidant potential; DPPH, 2,2-diphenyl-1-picrylhydrazyl; OH, hydroxyl; LP, lipid peroxidation.
| Samples | Assay | ||||
|---|---|---|---|---|---|
| DPPH IC50 | OH IC50 (µg/mL) | NO IC50 | LP IC50 | FRAP | |
|
|
|
|
| ||
|
| 15 ± 0.11 | 250 ± 4.32 | n.d. **** | 17 ± 0.83 | 35.09 ± 1.51 |
|
| 21 ± 0.19 | n.d. | n.d. | 59 ± 1.73 | 34.41 ± 2.18 |
| AA | / | 20.25 ± 8.39 | / | / | / |
| PG | 0.75 ± 0.03 | 8.67 ± 0.63 | / | / | / |
| BHT | 4.23 ± 0.09 | 0.04 ± 0.01 | / | 7.59 ± 0.46 | / |
* Ascorbic acid equivalents; ** Mean value; *** Standard deviation, **** Not detected.
Figure 1Results of principal components analysis (PCA); Ov—O. vulgare; Sm—S. montana.
Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of O. vulgare and S. montana EOs against mastitis-associated pathogens.
| Sample | OV * (MIC) (mg/mL) | OV * (MBC) (mg/mL) | SM ** (MIC) (mg/mL) | SM ** (MBC) (mg/mL) |
|---|---|---|---|---|
| 4 strain | 0.78 | 1.56 | 3.125 | 6.25 |
|
| 6.25 | 12.5 | 6.25 | 12.5 |
| 3.125 | 6.25 | 1.56 | 3.125 | |
| 3.125 | 6.25 | 0.39 | 0.78 | |
| 3.125 | 6.25 | 6.25 | >12.5 | |
| 6.25 | 12.5 | 6.25 | 12.5 | |
| 3.125 | 6.25 | 6.25 | 12.5 | |
| 3.125 | 6.25 | 6.25 | 12.5 | |
| 3.125 | 6.25 | 6.25 | 12.5 | |
|
| 3.125 | 6.25 | 3.125 | 6.25 |
* OV—O. Vulgare EO; ** SM—S. montana EO.
Figure 2Results of principal components analysis (PCA); OV-O. vulgare; SM-S. montana.